Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders

@article{Hashimoto2013GlutamateMA,
  title={Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders},
  author={Kenji Hashimoto and Berend Malchow and Peter G Falkai and Andrea Schmitt},
  journal={European Archives of Psychiatry and Clinical Neuroscience},
  year={2013},
  volume={263},
  pages={367-377}
}
Severe psychiatric disorders such as schizophrenia are related to cognitive and negative symptoms, which often are resistant to current treatment approaches. The glutamatergic system has been implicated in the pathophysiology of schizophrenia and affective disorders. A key component is the dysfunction of the glutamatergic N-methyl-d-aspartate (NMDA) receptor. Substances regulating activation/inhibition of the NMDA receptor have been investigated in schizophrenia and major depression and are… 
The glutamate system as a therapeutic target and impact of genes on suicidality
TLDR
Based on the fact that antagonists at the glutamatergic N-methyl-D-aspartate (NMDA) receptor cause psychosis, a dysfunction of the glutamate system has been proposed to play a role in schizophrenia and major depression, and a potential association of polymorphisms in brain-derived neurotrophic factor (BDNF) genes with worse treatment outcome in patients with melancholic depression is reported.
Glutamatergic drugs for schizophrenia treatment.
TLDR
Despite repeated failures, the glutamatergic approach to the treatment of schizophrenia has not been exhausted and all theoretical aspects that relate these complex neurochemical mechanisms with symptoms of schizophrenia should be reviewed until the authors find truly effective molecules with an acceptable side effect profile.
Targeting of NMDA receptors in new treatments for schizophrenia
  • K. Hashimoto
  • Biology, Medicine
    Expert opinion on therapeutic targets
  • 2014
TLDR
Given the NMDA receptor hypothesis of schizophrenia, the glycine modulatory site on NMDA receptors is the most attractive therapeutic target for this disease, and both the kynurenine pathway and cystine-glutamate antiporter represent credible potential therapeutic targets for schizophrenia.
Antipsychotic treatment modulates glutamate transport and NMDA receptor expression
TLDR
This review summarizes the current knowledge on effects of FGAs and SGAs on glutamate transport and receptor expression derived from pharmacological studies and indicates that serotonergic effects of SGAs represent important targets for further clinical research.
Glutamatergic agents for schizophrenia: current evidence and perspectives
TLDR
Because glutamate guides processes of brain development and maturation, clinical research should focus on the at-risk mental state or first-episode psychosis, address cognition and negative symptoms and use monotherapy designs in parallel to augmentation strategies.
Metabotropic glutamatergic receptors and their ligands in drug addiction.
TLDR
The molecular structure of mGluRs and their distribution, physiology and pharmacology in the central nervous system, as well as their use as targets in preclinical studies of drug addiction are described.
Ketamine and other potential glutamate antidepressants
TLDR
The article reviews the effect of current antidepressants on NMDA and examines the efficacy and mechanism of ketamine, and comparison with other glutamate drugs including lamotrigine, amantadine, riluzole, memantine, traxoprodil, GLYX-13, MK-0657, RO4917523, AZD2066 and Coluracetam.
NMDA receptor antagonists for depression: Critical considerations.
  • G. Serafini, X. Gonda, +4 authors M. Amore
  • Psychology, Medicine
    Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists
  • 2015
TLDR
Targeting NMDARs using antagonists represents an important alternative antidepressant option in major depression, however, N MDAR antagonists may exert different actions based on the differential brain location of NMDar.
Metabotropic Glutamate Receptors in Central Nervous System Diseases.
TLDR
The current knowledge on the involvement of mGlu receptors in the pathophysiology of neuropsychiatric disorders (schizophrenia, depression, anxiety and cognitive disorders, pain perception and addiction, as well as neurodegenerative and neurodevelopmental diseases is summarized.
D-Serine: Potential Therapeutic Agent and/or Biomarker in Schizophrenia and Depression?
TLDR
Preclinical and clinical studies with D-serine indicate that it may be effective in reducing cognitive dysfunction and may be a biomarker for antidepressant response to ketamine.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 147 REFERENCES
The role of glutamate on the action of antidepressants
  • K. Hashimoto
  • Medicine
    Progress in Neuro-Psychopharmacology and Biological Psychiatry
  • 2011
TLDR
The author reviews the role of glutamate in the neuron-glia communication induced by potential antidepressants and indicates that the agents which act at glutamate receptors such as NMDA receptors, α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors and metabotropic glutamate receptors (mGluRs) might have antidepressant-like activities in animal models of depression.
Glutamate signaling in the pathophysiology and therapy of schizophrenia
TLDR
The neurodevelopmental origin and genetic susceptibility of schizophrenia relevant to NMDA neurotransmission is reviewed, and the relationship between NMDA hypofunction and different domains of symptom in schizophrenia as well as putative treatment modality for the disorder is discussed.
Targeting of metabotropic glutamate receptors for the treatment of schizophrenia.
TLDR
The potential of both mGLU2/3 receptor agonists/potentiators and mGlu1 receptor antagonists for the treatment of schizophrenia are described.
From Revolution to Evolution: The Glutamate Hypothesis of Schizophrenia and its Implication for Treatment
TLDR
NMDAR has intrinsic modulatory sites that are active targets for drug development, several of which show promise in preclinical/early clinical trials targeting both symptoms and cognition, and allosteric modulators, both positive and negative, may offer superior efficacy with less danger of downregulation.
Emerging role of glutamate in the pathophysiology of major depressive disorder
TLDR
The author reviews the recent findings on the role of the glutamatergic system in the neurobiology of MDD and in new potential therapeutic targets (NMDA receptors, AMPA receptors, metabotropic glutamate receptors, ceftriaxone, minocycline, N-acetyl-L-cysteine) for MDD.
Glycine transporter-1: a new potential therapeutic target for schizophrenia.
TLDR
The author reviews the recent findings on the GlyT-1 as a potential therapeutic target of schizophrenia and suggests that increasing NMDA receptor function via pharmacological manipulation could provide a new therapeutic strategy for schizophrenia.
NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders.
TLDR
This review will examine pathophysiological and therapeutic hypotheses generated or supported by clinical studies employing NMDA antagonists and glycine-B agonists and partial agonists, and consider ethical issues related to human psychopharmacological studies employing glutamatergic probes.
Metabotropic glutamate receptors as therapeutic targets for schizophrenia
TLDR
Evidence from animal studies indicates that mGlu(5) PAMs hold promise for the treatment of cognitive deficits that occur in schizophrenia, and the pursuit of compounds that potentiate the receptor's response to glutamate by acting at less highly conserved allosteric sites.
Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial
TLDR
The data suggest that mGlu2/3 receptor agonists have antipsychotic properties and may provide a new alternative for the treatment of schizophrenia.
Glycine Transport Inhibitors for the Treatment of Schizophrenia
  • K. Hashimoto
  • Medicine
    The open medicinal chemistry journal
  • 2010
TLDR
This paper provides an overview of the various GlyT-1 inhibitors and their therapeutic potential and demonstrates that the Gly T-1 inhibitor sarcosine shows antipsychotic activity in patients with schizophrenia.
...
1
2
3
4
5
...